Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer.
- Resource Type
- Article
- Authors
- Meyer, Braydon; Clifton, Samuel; Locke, Warwick; Luu, Phuc-Loi; Du, Qian; Lam, Dilys; Armstrong, Nicola J.; Kumar, Beena; Deng, Niantao; Harvey, Kate; Swarbrick, Alex; Ganju, Vinod; Clark, Susan J.; Pidsley, Ruth; Stirzaker, Clare
- Source
- Clinical Epigenetics. 12/18/2021, Vol. 13 Issue 1, p1-7. 7p.
- Subject
- *TRIPLE-negative breast cancer
*CANCER chemotherapy
*NEOADJUVANT chemotherapy
*DNA methylation
*EPIGENOMICS
*BIOMARKERS
- Language
- ISSN
- 1868-7075
Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient's response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation profiling on diagnostic TNBC biopsy samples from the Sequential Evaluation of Tumours Undergoing Preoperative (SETUP) NAC study. We found 9 significantly differentially methylated regions (DMRs) at diagnosis which were associated with response to NAC. We show that 4 of these DMRs are associated with TNBC overall survival (P < 0.05). Our results highlight the potential of DNA methylation biomarkers for predicting NAC response in TNBC. [ABSTRACT FROM AUTHOR]